

Bruce K Crawford

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1969020/publications.pdf>

Version: 2024-02-01

41
papers

2,426
citations

304743

22
h-index

302126

39
g-index

41
all docs

41
docs citations

41
times ranked

3774
citing authors

#	ARTICLE	IF	CITATIONS
1	PRO development: rigorous qualitative research as the crucial foundation. <i>Quality of Life Research</i> , 2010, 19, 1087-1096.	3.1	347
2	Concomitant Leflunomide Therapy in Patients with Active Rheumatoid Arthritis despite Stable Doses of Methotrexate. <i>Annals of Internal Medicine</i> , 2002, 137, 726.	3.9	287
3	Bayesian Meta-Analysis of Multiple Treatment Comparisons: An Introduction to Mixed Treatment Comparisons. <i>Value in Health</i> , 2008, 11, 956-964.	0.3	283
4	Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2000, 43, 506.	6.7	155
5	Mapping to Estimate Health-State Utility from Non-Preference-Based Outcome Measures: An ISPOR Good Practices for Outcomes Research Task Force Report. <i>Value in Health</i> , 2017, 20, 18-27.	0.3	145
6	Function and health-related quality of life: Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1999, 42, 1870-1878.	6.7	132
7	Patient Self-Reports in Pharmacoeconomic Studies. <i>Pharmacoeconomics</i> , 1999, 15, 241-256.	3.3	125
8	Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report. <i>Value in Health</i> , 2019, 22, 267-275.	0.3	98
9	Development of the ASK-20 Adherence Barrier Survey. <i>Current Medical Research and Opinion</i> , 2008, 24, 2127-2138.	1.9	91
10	Use of Quality Adjusted Life Years and Life Years Gained as Benchmarks in Economic Evaluations: A Critical Appraisal. <i>Health Care Management Science</i> , 2004, 7, 43-49.	2.6	73
11	Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 317-326.	1.4	72
12	Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 590-601.	2.0	68
13	Development and validation of a cough and sputum assessment questionnaire. <i>Respiratory Medicine</i> , 2008, 102, 1545-1555.	2.9	67
14	Fexofenadine Improves the Quality of Life and Work Productivity in Japanese Patients with Seasonal Allergic Rhinitis during the Peak Cedar Pollinosis Season. <i>International Archives of Allergy and Immunology</i> , 2005, 136, 148-154.	2.1	56
15	Quality-of-life improvements in cataract patients with bilateral blue light-filtering intraocular lenses: Clinical trial. <i>Journal of Cataract and Refractive Surgery</i> , 2005, 31, 1952-1959.	1.5	55
16	Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. <i>British Journal of Haematology</i> , 2008, 143, 511-519.	2.5	55
17	Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies. <i>Journal of Cardiology</i> , 2015, 66, 466-474.	1.9	36
18	Expert Judgement in Pharmacoeconomic Studies. <i>Pharmacoeconomics</i> , 2000, 17, 545-553.	3.3	34

#	ARTICLE	IF	CITATIONS
19	Conceptual adequacy of the neuropathic pain symptom inventory in six countries. <i>Health and Quality of Life Outcomes</i> , 2008, 6, 62.	2.4	32
20	Responsiveness of the cough and sputum assessment questionnaire in exacerbations of COPD and chronic bronchitis. <i>Respiratory Medicine</i> , 2010, 104, 534-541.	2.9	26
21	Validation of a COPD screening questionnaire and establishment of diagnostic cut-points in a Japanese general population: The Hisayama study. <i>Allergology International</i> , 2015, 64, 49-53.	3.3	25
22	Data Collection Methods in Prospective Economic Evaluations: How Accurate Are the Results?. <i>Value in Health</i> , 2000, 3, 277-286.	0.3	23
23	Evaluation of the willingness to pay for cancer treatment in Korean metastatic breast cancer patients: A multicenter, cross-sectional study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012, 8, 282-291.	1.1	18
24	Cost-effectiveness of EOB-MRI for Hepatocellular Carcinoma in Japan. <i>Clinical Therapeutics</i> , 2017, 39, 738-750.e4.	2.5	18
25	Optimal Treatment for Complicated Intra-abdominal Infections in the Era of Antibiotic Resistance: A Systematic Review and Meta-Analysis of the Efficacy and Safety of Combined Therapy With Metronidazole. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw143.	0.9	13
26	Treatment Patterns and Lipid Profile in Patients with Familial Hypercholesterolemia in Japan. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 580-592.	2.0	13
27	Impact of Pediatric Acute Otitis Media on Child and Parental Quality of Life and Associated Productivity Loss in Malaysia: A Prospective Observational Study. <i>Drugs - Real World Outcomes</i> , 2017, 4, 21-31.	1.6	12
28	Utilization patterns of insulin therapy and healthcare services among Japanese insulin initiators during their first year: a descriptive analysis of administrative hospital data. <i>BMC Health Services Research</i> , 2015, 16, 6.	2.2	9
29	WILLINGNESS TO PAY FOR LUNG CANCER TREATMENT: PATIENT VERSUS GENERAL PUBLIC VALUES. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 264-270.	0.5	8
30	Validation of the sleep impact scale in patients with major depressive disorder and insomnia. <i>Current Medical Research and Opinion</i> , 2009, 25, 1699-1710.	1.9	7
31	Neuropathic pain: A patient-centred approach to measuring outcomes. <i>Health Expectations</i> , 2018, 21, 774-786.	2.6	7
32	The development of the ICIQ-UAB: A patient reported outcome measure for underactive bladder. <i>Neurourology and Urodynamics</i> , 2019, 38, 996-1004.	1.5	7
33	The Use of patient Reported Outcome Measures for Rheumatoid Arthritis in Japan: A Systematic Literature Review. <i>Open Rheumatology Journal</i> , 2017, 11, 43-52.	0.2	6
34	Direct Medical Costing for Economic Evaluations: Methodologies and Impact on Study Validity. <i>Drug Information Journal</i> , 2000, 34, 173-184.	0.5	5
35	Economic Burden of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery. <i>Value in Health Regional Issues</i> , 2015, 6, 73-79.	1.2	5
36	Hepatitis C virus in Asia: utility values based on the Short Form-36 questionnaire. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 765-773.	1.4	4

#	ARTICLE	IF	CITATIONS
37	Economic Impact of Venous Thromboembolism Following Major Orthopaedic Surgery in Japan. Value in Health Regional Issues, 2013, 2, 81-86.	1.2	4
38	The revalidation of the diabetes treatment-related quality-of-life (DTR-QOL) questionnaire in Japan. Diabetology International, 2019, 10, 93-101.	1.4	3
39	Meeting the US FDA's evidence standard with health-related quality of life claims. Expert Review of Pharmacoeconomics and Outcomes Research, 2002, 2, 401-402.	1.4	2
40	Usefulness of resource utilization estimates from piggyback studies in rheumatoid arthritis. Expert Review of Pharmacoeconomics and Outcomes Research, 2003, 3, 685-689.	1.4	0
41	Characteristics of 2-drug regimen users living with HIV-1 in a real-world setting: A large-scale medical claim database analysis in Japan. PLoS ONE, 2022, 17, e0269779.	2.5	0